FIRST-TRIMESTER DOWN S SYNDROME SCREENING
|
|
- Leonard Chase
- 7 years ago
- Views:
Transcription
1 FIRST-TRIMESTER DOWN S SYNDROME SCREENING BY FETAL NUCHAL TRANSLUCENCY MEASUREMENT IN TAIWAN Hei-Jen Jou, 1,2 Jin-Chung Shih, 2 Shiao-Chi Wu, 3 Te-Cheng Li, 1 Chau-Yang Tzeng, 1 and Fon-Jou Hsieh 2 Background: Fetal nuchal translucency (NT) measurement is now widely used in many Western countries as a screening tool for Down s syndrome during the first trimester. However, at present there is no data on its use in Taiwan. The purpose of the present study was to evaluate the efficacy of NT measurement in first-trimester Down s syndrome screening in Taiwan. Methods: We conducted a prospective study from October 1997 to May Sonographic measurement of fetal NT was performed in 1,249 fetuses at 9 14 weeks of gestation. Transabdominal ultrasound scanning was performed to obtain a sagittal section of the fetus for measuring the crown rump length (CRL) and the maximum thickness of the subcutaneous translucency between the skin and the soft tissue overlying the cervical spine. Two different cut-off points were used for screening: a fixed cut-off point of at least 2.5 mm and a CRL-related cut-off point. In the latter method, fetuses with an NT measurement in the 95th percentile were considered at high risk for Down s syndrome. Results: Three fetuses had Down s syndrome, with NT measurements of 2.1 mm, 2.7 mm, and 4.0 mm. The false positive rates for the fixed cut-off point and CRLrelated cut-off point were 6.3% and 4.6%, respectively. Both methods had a sensitivity of 66.7%. However, the screening program using the CRL-related cut-off point had two advantages: a higher specificity (95.5% vs 93.8%) and a more reasonable distribution pattern for screening. Conclusion: This study showed that NT measurement is a potential screening tool for Down s syndrome during the first trimester in Taiwan. Using CRL-related cutoff points for screening is more resonable than using a fixed cut-off point. (J Formos Med Assoc 2001;100:257 61) Key words: Down s syndrome screening nuchal translucency first trimester ultrasonography Down s syndrome is the most common cause of mental retardation, with a prevalence of 1:848 newborns [1]. Definitive antenatal diagnosis of Down s syndrome requires invasive procedures such as first-trimester chorionic villi sampling (CVS) or second-trimester amniocentesis. Because each test is associated with a risk of unwanted fetal loss, it is usually offered under indications such as advanced maternal age, family history of chromosomal aberrations, or a positive result on noninvasive screening. Second-trimester maternal serum screening is now the most popular screening tool for Down s syndrome in Taiwan, with a sensitivity of 62.5% and a false positive rate of 6.3% [2]. About half of pregnant women receive the test, which is based on the measurement of serum concentrations of α-fetoprotein and human chorionic gonadotropin [2, 3]. There are several limitations with the secondtrimester maternal serum marker test. Major problems include the relatively late gestational age at final cytogenetic diagnosis, often as late as 22 to 24 weeks. Also, more than 100 amniocenteses are required for every case of Down s syndrome identified [2]. Therefore, Departments of Obstetrics and Gynecology, 1 Taiwan Adventist Hospital and 2 National Taiwan University Hospital, and 3 Institute of Health and Welfare Policy, National Yang-Ming University, Taipei. Received: 7 August Revised: 6 September Accepted: 9 January Reprint requests and correspondence to: Dr. Hei-Jen Jou, Department of Obstetrics and Gynecology, Taiwan Adventist Hospital, 424, Section 2, Pa-Te Road, Taipei, Taiwan. J Formos Med Assoc 2001 Vol 100 No 4 257
2 H.J. Jou, J.C. Shih, S.C. Wu, et al developing a new screening program with higher detection rates at an earlier gestational age is warranted. In 1992, Nicolaides et al first demonstrated the association between an increased nuchal translucency (NT) measurement during the first trimester of pregnancy and chromosomal aberrations [4]. Fetuses with an NT measurement of 3 to 8 mm at 10 to 14 weeks of gestation had an increased risk of Down s syndrome. Based on this report and subsequent studies, ultrasound measurement of fetal NT during the first trimester has become a useful marker for antenatal screening of Down s syndrome and is widely used in many Western countries [5 10]. However, the efficacy and sensitivity of this screening technique have not been reported in Taiwanese or other Asian populations. Here, we report the results of first-trimester Down s screening using ultrasound measurement of NT based on 1,249 fetuses between 9 and 14 weeks of gestation. 258 Materials and Methods A prospective study was conducted from August 1997 to May Ultrasound measurement of fetal NT was offered between 9 and 14 weeks of gestation to pregnant women who received antenatal care at our institution. The gestational age was determined by the last menstrual period. Recorded data included maternal age, gestational age, fetal crown rump length (CRL), NT, and fetal anomalies. We used a curvilinear 5-MHz transabdominal transducer (Acuson 128 XP/10, Acuson, Mountain View, CA, USA). The maximal thickness of the subcutaneous translucency between the skin and the soft tissue of the cervical spine was measured to 0.1 mm on sagittalsection scans of fetuses (Figure). The measurement was performed with the fetus slightly flexed. We carefully distinguished the fetal skin from the overlying amniotic membrane. Sometimes, it was necessary to manipulate the woman s abdomen to encourage the fetus to change position for adequate measurement. Occasionally, two or three measurements were performed on one fetus, and the largest measurement was used for analysis. Initially, we used 2.5 mm as the cut-off point for the screening. Fetuses with an NT measurement of at least 2.5 mm were considered at high risk for Down s syndrome. Genetic consultation was offered, and CVS or amniocentesis was suggested for cytogenetic study. The normal distribution of NT measurements for a chromosomally normal fetus was calculated based on data of the first 879 fetuses [11]. The standard devia- Figure. Measurement of the nuchal translucency thickness in a 12- week fetus using transabdominal ultrasound. The largest distance from the inner side of the skin to the soft tissue of the cervical spine was measured to 0.1mm. tion of an NT measurement may be expressed as shown below: 1 (x* x ) 2 1 (x ) 2 S = S y/x = (1 + + ) ^y n ( x x ) * Then, the 95th percentile value of the NT on a CRL is equal to 1 (x ) 2 b 0 +b 1 x+1.64* S = x (1+ + ) ^y * All measurements were reevaluated with the normal distribution. A fetus with an NT measurement in the 95th percentile was at high risk for Down s syndrome. The sensitivity and specificity of both methods were calculated using Fisher s exact test. A p value of less than 0.05 was considered statistically significant. We also compared the two methods. Results A total of 1,979 consecutive measurements were performed during the study. Seven hundred and thirty cases were excluded because of loss to follow-up or incomplete data. A total of 1,249 women were enrolled, including 1,231 singleton and nine twin pregnancies. The mean maternal age was ± 3.53 years (range, yr). The mean and median of the CRL were ± mm and mm (range, mm), respectively. The distributions of the NT measurement for various gestational ages and CRL groups are summarized in Tables 1 and 2. Three fetuses with Down s syndrome had NT measurements of 2.1 mm, 2.7 mm, and 4.0 mm. With a fixed J Formos Med Assoc 2001 Vol 100 No 4
3 cut-off point of 2.5 mm, 79 fetuses had a positive screening result. The false positive rate was 6.3%, sensitivity was 66.7%, and specificity was 93.8%. However, only 58 fetuses had an NT measurement in the 95th percentile. The false positive rate was 4.6%, sensitivity was 66.7%, and specificity was 95.5%. Both methods had similar negative predictive values (99.91% vs 99.92%). Discussion Experience with first-trimester Down s screening using fetal NT measurement is limited in Taiwan, and the efficacy of such a screening program here remains to be determined. Our results showed a detection rate of 66.7%, with a false positive rate of 6.2% using a fixed cut-off point. When a CRL-related cut-off point was used, the detection rate remained the same, but the false positive rate was only 4.6%. These findings show that this screening program is a potentially useful tool for Down s syndrome screening during the first trimester. Several reports have described an association between increased fetal NT and aneuploidy. Although NT measurement is feasible and promising, studies of its efficacy have yielded conflicting results with detection rates ranging from 33% to 91% (Table 3). The positive predictive values range from 1.5% to 9.2%. Only 10 to 70 invasive cytogenetic procedures are needed to detect one Down s syndrome child [7 9, 12 16]. This study required fewer invasive diagnostic procedures to detect one case of Down s syndrome than a previous large population study in Taiwan that used serum screening during the second trimester [2]. The high negative predictive value showed that the risk of Down s syndrome is less than 0.1% if a fetus does not have a thickened NT. Table 1. Number of fetuses with increased nuchal translucency (NT) measurement based on gestational age (GA) GA Total NT 2.5 mm > 95th percentile (wk) fetuses (n) n (%) n (%) (1.1) 4 (2.2) (2.4) 9 (3.5) (4.8) 21 (5.6) (12.4) 19 (5.9) (11.7) 5 (4.9) Total 1, (6.3) 58 (4.6) Table 2. Number of fetuses with increased nuchal translucency (NT) measurement based on crown rump length (CRL) CRL Total NT 2.5 mm > 95th percentile (mm) fetuses (n) n (%) n (%) (3.8) (2.4) 8 (3.8) (2.0) 12 (4.8) (5.7) 15 (5.3) (8.6) 12 (4.9) (14.5) 6 (3.8) (15.0) 3 (7.5) (30.0) 0 Total 1, (6.4) 58 (4.6) Initially, a fixed cut-off point was used for the screening [8, 9, 12, 14]. The basic assumption in using a fixed cut-off point was that the distribution of NT was similar throughout the screening period. However, it has been noted that the NT thickness increases with gestational age [7, 11, 17 21]. In spite of an overall false positive rate of 6.3%, the present study revealed that the false positive rate was not adequate in both tails of the period. Using gestational age- (or CRL-) related cut-off points is more reasonable than using a fixed cutoff point [11]. Studies reported since 1998 have used a gestational age- or CRL-related cut-off point. The present study also showed that the CRL-related cut-off point had a lower false positive rate [7, 16, 17]. The widespread use of Down s syndrome screening by ultrasound measurement of fetal NT during the first trimester has been questioned in Taiwan, where there are no reported data for this screening test. Also, most obstetricians in Taiwan do not offer CVS because a previous large population survey showed a strong association between CVS and fetal limb reduction anomalies [22]. When a fetus is found to have a thickened NT, the pregnant woman needs to wait about 3 to 4 weeks for amniocentesis and then another 4 weeks for the report. This is too long for a screening program. In most European countries, CVS is used for cytogenetic study in fetuses with a thickened NT measurement. It can be offered immediately after a positive screening result and only 3 to 4 days are needed for the report. Therefore, the association between CVS and fetal limb reduction anomalies should be clarified before this screening program is widely used. One recent report shows that CVS does not significantly increase the incidence of fetal limb reduction when it is offered after 10 weeks of gestation [23]. This study had several limitations. The number of cases in this study was relatively small for a Down s syndrome screening program, and the prevalence of J Formos Med Assoc 2001 Vol 100 No 4 259
4 H.J. Jou, J.C. Shih, S.C. Wu, et al Table 3. Published results of Down s screening by first-trimester nuchal translucency (NT) measurement in the general population Study Subjects (n) GA (wk) Cut-off point FPR Detection rate Bewley et al, 1995 [12] 1, NT 3 mm 6.2% 33% (1/3) Whitlow et al, 1999 [17] 6, NT 99th centile 1.0% 57% (13/23) Taipale et al, 1997 [14] 10, NT 3 mm 0.8% 54% (7/13) Hafner et al, 1998 [9], 4, NT 2.5 mm 1.7% 43% (3/7) Pajkrt et al, 1998 [8] 1, NT 3 mm 4.0% 69% (25/36) Snijders et al, 1998 [7] 96, NT > 95th centile 4.4% 72% (234/326) Risk (NT + MA) > 1/ % 82% (168/326) Theodoropoulos et al, 1998 [15] 3, NT > 95th centile 2.9% 91% (10/11) Thilaganathan et al, 1999 [16] 11, Risk (NT) 1: % 76% (16/21) Jou et al (present study) 1, NT 2.5 mm 6.3% 67% (2/3) NT > 95th centile 4.6% 67% (2/3) GA = gestational age; FPR = false positive rate; MA = maternal age. Down s syndrome was high (3/1,249). Also, about onethird of initial cases were excluded. A population bias should be considered. Further data is needed for a definitive conclusion. However, our data provide a first report and reveal that fetal NT measurement by ultrasound during the first trimester is a potentially effective and noninvasive screening tool for Down s syndrome in Taiwan. 260 References 1. Cheu BC, Shyu MK, Lee CN, et al: Maternal age-specific risk of Down syndrome in an Asian population: a report of the Taiwan Down syndrome screening group. Prenat Diagn 1998;18: Jou HJ, Shyu MK, Chen SM, et al: Maternal serum screening for Down syndrome by using alpha-fetoprotein and human chorionic gonadotropin in an Asian population. Fetal Diagn Ther 2000;15: Hsu JJ, Hsieh TT, Hsieh FJ: Down s syndrome screening in an Asian population using alpha-fetoprotein and free β-hcg: a report of the Taiwan Down s syndrome screening group. Obstet Gynecol 1996;87: Nicolaides KH, Azar G, Byrne D, et al: Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304: Pandya PP, Brizot ML, Kuhn P, et al: First-trimester fetal nuchal translucency thickness and risk for trisomies. Obstet Gynecol 1994;84: Pandya PP, Kondylios A, Hilbert L, et al: Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995;5: Snijders RJM, Noble P, Sebire N, et al: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at weeks of gestation. Lancet 1998;352: Pajkrt E, Mol BW, van Lith JM, et al: Screening for Down s syndrome by fetal nuchal translucency measurement in a high-risk population. Ultrasound Obstet Gynecol 1998;12: Hafner E, Schuchter K, Liebhart E: Results of routine fetal nuchal translucency measurement at weeks in 4,233 unselected pregnant women. Prenat Diagn 1998; 18: Pandya PP, Goldberg H, Walton B, et al: The implementation of first-trimester scanning at weeks gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol 1995;5: Jou HJ, Wu SC, Li TC, et al: Relationship between fetal nuchal translucency and crown rump length in an Asian population. Ultrasound Obstet Gynecol 2001;17: Bewley S, Roberts LJ, Mackison A-M, et al: First trimester fetal nuchal translucency: problems with screening the general population 2. Br J Obstet Gynaecol 1995;102: Kornman LH, Morssink LP, Beekhuis JR, et al: Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996;16: Taipale P, Hiilesmaa V, Salonen R, et al: Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med 1997;337: Theodoropoulos P, Lolis D, Papageorgiou C, et al: Evaluation of first-trimester screening by fetal nuchal-translucency thickness and maternal age. Prenat Diagn 1998;18: Thilaganathan B, Sairam S, Michailidis G, et al: First trimester nuchal translucency: effective routine screening for Down s syndrome. Br J Radiol 1999;72: Whitlow BJ, Chatzipapas IK, Lazanakis ML, et al: The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population. Br J Obstet Gynaecol 1999;106: J Formos Med Assoc 2001 Vol 100 No 4
5 18. Braithwaite JM, Morris RW, Economides DL: Nuchal translucency measurements: frequency distribution and changes with gestation in the general population. Br J Obstet Gynaecol 1996;103: Roberts LJ, Bewley S, Mackison A-M, et al: First trimester fetal nuchal translucency: problems with screening the general population 1. Br J Obstet Gynaecol 1995;102: Brambati B, Cislaghi C, Tului L, et al: First-trimester Down s syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling. Ultrasound Obstet Gynecol 1995;5: Schuchter K, Wald N, Hackshaw AK, et al: The distribution of nuchal translucency at weeks of pregnancy. Prenat Diagn 1998;18: Hsieh FJ, Shyu MK, Sheu BC, et al: Limb defects after chorionic villus sampling. Obstet Gynecol 1995;85: Kuliev A, Jackson L, Froster U, et al: Chorionic villus sampling safety. Report of World Health Organization/ EURO meeting in association with the Seventh International Conference on Early Prenatal Diagnosis of Genetic Diseases, May 21, 1994, Tel-Aviv, Israel. Am J Obstet Gynecol 1996;174: J Formos Med Assoc 2001 Vol 100 No 4 261
Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow
Ultrasound Obstet Gynecol 1998;12:380 384 Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow A. Matias*, C. Gomes*, N. Flack*, N. Montenegro and K. H. Nicolaides*
More informationThe 11 13 +6 weeks scan
The 11 13 +6 weeks scan Kypros H. Nicolaides The 11 13 +6 weeks scan Fetal Medicine Foundation, London 2004 Dedication to Herodotos & Despina Contents Introduction 1. First trimester diagnosis of chromosomal
More informationSonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation
American Journal of Obstetrics and Gynecology (2006) 194, 397 401 www.ajog.org Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation Aris T. Papageorghiou, MD, a Kyriaki Avgidou, MD, a
More informationScreening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at 11 + 0to13+ 6 weeks
Ultrasound Obstet Gynecol 2006; 27: 151 155 Published online 30 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.2699 Screening for trisomy 21 by fetal tricuspid regurgitation,
More informationClinical Studies Abstract Booklet
Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January
More informationUltrasound evaluation of fetal gender at 12 14 weeks
Ultrasound evaluation of fetal gender at 12 14 weeks Marek Lubusky a,b, Martina Studnickova a, Ales Skrivanek a, Katherine Vomackova c, Martin Prochazka a Aims. The aim of this study was to assess the
More informationFrontomaxillary and mandibulomaxillary facial angles at 11 + 0to13+ 6 weeks in fetuses with trisomy 18
Ultrasound Obstet Gynecol 2007; 30: 928 933 Published online 1 November 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.2/uog.5188 Frontomaxillary and mandibulomaxillary facial angles
More informationMaternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester
PRENATAL DIAGNOSIS Prenat Diagn 2000; 20: 390±394. Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester Kevin Spencer 1 *, Natasha Tul 2 and Kypros H. Nicolaides 2
More informationFirst Trimester Screening for Down Syndrome
First Trimester Screening for Down Syndrome What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test
More informationyour questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal
More informationNon-Invasive Prenatal Testing (NIPT) Factsheet
Introduction NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.
More informationCorrespondence: Dr K. Spencer, Endocrine Unit, Clinical Biochemistry Department, Harold Wood Hospital, Gubbins Lane, Romford, Essex, RM3 0BE, UK
Ultrasound Obstet Gynecol 1999;:231 237 A screening program for trisomy 21 at 10 14 using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-a
More informationfi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...
АВАВАКдлАмА дла длама АсАядлАмА АВА АсдлАя & MАядлдлАмАК TА. 4, T. 2, АВ. 113-118, 2005 fi АУ : Аяapplefi. fiapple АсА» Ас Ам, длappleapple Ас..., Ая: Аяapplefi. fiapple, АВАУ Ас, АсА» Ас Ам длappleapple
More informationExecutive summary. Current prenatal screening
Executive summary Health Council of the Netherlands. NIPT: dynamics and ethics of prenatal screening. The Hague: Health Council of the Netherlands, 2013; publication no. 2013/34. In recent years, new tests
More informationcfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation.
Reports of Major Impact www.ajog.org Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population Kypros H. Nicolaides, MD; Argyro Syngelaki, RM; Ghalia Ashoor, MD;
More informationPrenatal screening and diagnostic tests
Prenatal screening and diagnostic tests Contents Introduction 3 First trimester routine tests in the mother 3 Testing for health conditions in the baby 4 Why would you have a prenatal test? 6 What are
More informationPrenatal Testing Special tests for your baby during pregnancy
English April 2006 [OTH-7750] There are a number of different prenatal (before birth) tests to check the development of your baby. Each test has advantages and disadvantages. This information is for people
More informationEmbryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities
CME Article Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities Deniz Oztekin, MD, Ozgur Oztekin, MD, Fatma I. Aydal, MD, Sivekar Tinar, MD, Zehra H. Adibelli, MD Objective. The purpose
More informationCharts of fetal size: limb bones
BJOG: an International Journal of Obstetrics and Gynaecology August 2002, Vol. 109, pp. 919 929 Charts of fetal size: limb bones Lyn S. Chitty a, *, Douglas G. Altman b Objective To construct new size
More informationAnalytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers
DOI: 10.1002/pd.4019 ORIGINAL ARTICLE Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers Kevin Spencer* and Nicholas J. Cowans
More informationImplementation of maternal blood cell-free DNA testing in early screening for aneuploidies
Ultrasound Obstet Gynecol 2013; 42: 34 40 Published online 7 June 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12504 Implementation of maternal blood cell-free DNA testing in
More informationA test your patients can trust.
A test your patients can trust. A simple, safe, and accurate non-invasive prenatal test for early risk assessment of Down syndrome and other conditions. informaseq Prenatal Test Simple, safe, and accurate
More informationTHE USE OF FIRST TRIMESTER ULTRASOUND
SOGC CLINICAL PRACTICE GUIDELINES THE USE OF FIRST TRIMESTER ULTRASOUND This guideline has been reviewed by the Diagnostic Imaging Committee and approved by the Executive and Council of the Society of
More informationFetal echocardiography at 11 13 weeks by transabdominal high-frequency ultrasound
Ultrasound Obstet Gynecol 2011; 37: 296 301 Published online 10 February 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.8934 Fetal echocardiography at 11 13 weeks by transabdominal
More informationPrognosis of Very Large First-Trimester Hematomas
Case Series Prognosis of Very Large First-Trimester Hematomas Juliana Leite, MD, Pamela Ross, RDMS, RDCS, A. Cristina Rossi, MD, Philippe Jeanty, MD, PhD Objective. The aim of this study was to evaluate
More informationIncreased fetal nuchal translucency at 11 14 weeks
PRENATAL DIAGNOSIS Prenat Diagn 2002; 22: 308 315. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/ pd.308 Increased fetal nuchal translucency at 11 14 weeks Kypros H.
More informationThe National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report
0 The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report Joan K Morris, Elizabeth De Souza December 2009 National Down Syndrome Cytogenetic Register Queen Mary University
More information11 13 +6 Weeks Scan Project Newsletter
USA FETAL MEDICINE FOUNDATION OF THE UNITED STATES OF A MERICA Non-profit Registration No.1635069 July 2007 11 13 +6 Weeks Scan Project Naomi Greene MPH RDMS RDCS 3940 Laurel Canyon Blvd. #838 Studio City,
More informationjournal of medicine The new england First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome abstract
The new england journal of medicine established in 1812 november 10, 2005 vol. 353 no. 19 First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome Fergal D. Malone, M.D., Jacob A. Canick,
More informationThe first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands
FVV in ObGyn, 2014, 6 (1): 7-12 Preliminary report The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands P.J. Willems 1, H. Dierickx 1, ES. Vandenakker
More informationFetal Lateral Ventricular Width: What Should Be Its Upper Limit?
Article Fetal Lateral Ventricular Width: What Should Be Its Upper Limit? A Prospective Cohort Study and Reanalysis of the Current and Previous Data Benny Almog, MD, Ronni Gamzu, MD, PhD, Reuven Achiron,
More informationInclusion of Early Fetal Deaths in a Birth Defects Surveillance System
TERATOLOGY 64:S20 S25 (2001) Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System MATHIAS B. FORRESTER AND RUTH D. MERZ* Hawaii Birth Defects Program, Honolulu, Hawaii 96817 ABSTRACT
More informationLe dépistage prénatal First-trimester syndrome de Down. grossesse aneuploidies SUMMARY AGENCE D ÉVALUATION DES TECHNOLOGIES
Le dépistage prénatal du First-trimester syndrome de Down et prenatal d autres screening aneuploïdies au for premier Down trimestre syndrome de la and grossesse other aneuploidies SUMMARY AGENCE D ÉVALUATION
More informationDown s Syndrome: Ultrasound Screening
October 2001 Down s Syndrome: Ultrasound Screening Hilary Hochberg Advanced Radiology Clerkship Dr. Gillian Lieberman Patient M.C. 32 year old female presents at 16 weeks gestational age with abnormal
More informationClinical Significance of First Trimester Umbilical Cord Cysts
Clinical Significance of First Trimester Umbilical Cord Cysts Waldo Sepulveda, MD, Sergio Leible, MD, Angel Ulloa, MD, Milenko Ivankovic, MD, Carlos Schnapp, MD A cystic mass of the umbilical cord was
More informationDepartment of Obstetrics and Gynecology, Kayseri Military Hospital, Kayseri, Turkey
Orıgınal Article Obstetrics & Gynecology North Clin Istanbul 2015;2(2):92-100 doi: 10.14744/nci.2015.08370 A prospective study to assess the clinical impact of interobserver reliability of sonographic
More informationNoninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions
More informationGenetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Testing and pregnancy GP s role 3 Counselling before and during pregnancy 3 Collecting the family history
More informationTrisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)
Trisomies 13 and 18 (Patau and Edward s syndrome) Trisomy 21 (Down syndrome) is the commonest chromosomal disorder at birth, and has been considered in detail in previous annual reports 23. Other relatively
More informationCONFIDENT CODING FOR OB/GYN CONFIDENT CODING FOR OB/GYN
Arlene J. Smith, CPC AAPC National Advisory Board 2007-2009 1 So when exactly does the global period start? Unraveling the confusion in antepartum care coding Correct coding for multiple gestations! Vaginal
More informationFirst-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ
First-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ First-trimester prenatal screening for Down syndrome
More informationObstetrical Ultrasound and Prenatal Diagnostic Center
Obstetrical Ultrasound and Prenatal Diagnostic Center Prenatal Diagnosis: Options and Opportunities Learn about various screening options including Early Risk Assessment (ERA), now available to women of
More informationSequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013
More informationLEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns
More informationThe California Prenatal Screening Program
The California Prenatal Screening Program Provider ook netic Disease Screening Program Quad Marker Screening Serum Integrated Screening Full Integrated Screening TABLE OF CONTENTS WELCOME to the California
More informationPrenatal Screening for Fetal Aneuploidy in Singleton Pregnancies
No. 261 (Replaces No. 187, February 2007) Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies This clinical practice guideline has been prepared by the Genetics Committee of the Society of
More informationPatient information on soft markers
Patient information on soft markers Before you read this section remember the following important points. The vast majority of babies with soft markers are normal. Soft markers are frequently seen in healthy
More informationLong-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester
Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester Peter M. Doubilet, MD, PhD, Carol B. Benson, MD, Jeanne S. Chow, MD Slow embryonic heart rates
More informationNeural tube defects: open spina bifida (also called spina bifida cystica)
Screening Programmes Fetal Anomaly Neural tube defects: open spina bifida (also called spina bifida cystica) Information for health professionals Publication date: April 2012 Review date: April 2013 Version
More informationA Guide to Prenatal Genetic Testing
Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests
More informationNoninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationFetuses With Trisomy 21 Having Conflicting Findings on Antenatal Testing for Fetal Well-being
Case Series Fetuses With Trisomy 21 Having Conflicting Findings on Antenatal Testing for Fetal Well-being Geoffrey Wong, MD, Deborah Levine, MD Objective. This series reports 3 cases with conflicting antenatal
More informationEvaluation and Follow-up of Fetal Hydronephrosis
Evaluation and Follow-up of Fetal Hydronephrosis Deborah M. Feldman, MD, Marvalyn DeCambre, MD, Erin Kong, Adam Borgida, MD, Mujgan Jamil, MBBS, Patrick McKenna, MD, James F. X. Egan, MD Objective. To
More informationUltrasonography of the Fetal Thyroid
Article Ultrasonography of the Fetal Thyroid Nomograms Based on Biparietal Diameter and Gestational Age Angela C. Ranzini, MD, Cande V. Ananth, PhD, MPH, John C. Smulian, MD, MPH, Michelle Kung, Anita
More informationFetal size and dating: charts recommended for clinical obstetric practice
Fetal size and dating: charts recommended for clinical obstetric practice Pam Loughna 1, Lyn Chitty 2, Tony Evans 3 & Trish Chudleigh 4 1 Academic Division of Obstetrics and Gynaecology, Nottingham University
More informationUltrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester?
Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester? Laurence E. Shields, MD, Leslie A. Carpenter, MS, CGC, Karin M. Smith, RDMS, Hanh V. Nghiem, MD The objective of
More informationechocardiography practice and try to determine the ability of each primary indication to identify congenital heart disease. Patients and Methods
29 ABNORMAL CARDIAC FINDINGS IN PRENATAL SONOGRAPHIC EXAMINATION: AN IMPORTANT INDICATION FOR FETAL ECHOCARDIOGRAPHY? RIMA SAMI BADER Aim: The present study was conducted to evaluate the most common indications
More informationCOMMITTEE OPINION. Cell-free DNA Screening for Fetal Aneuploidy
The American College of Obstetricians and Gynecologists WOMEN S HEALTH CARE PHYSICIANS (Published Electronically Ahead of Print on June 26, 2015) COMMITTEE OPINION Number 640 September 2015 (This Committee
More informationChoices about first trimester ultrasound scans: A decision aid for pregnant women
Choices about first trimester ultrasound scans: A decision aid for pregnant women If you have any concerns about yourself or your baby/babies and want to talk to someone, please call: your family doctor
More informationMASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA
Scuola di specializzazione in Genetica Medica Journal Club 14 gennaio 2014 MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA Bianchi, Diana W. MD; Prosen,
More informationThe California Prenatal Screening Program
The California Prenatal Screening Program Quad Marker Screening One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester) Serum Integrated Screening Prenatal Patient Booklet - English
More informationPrediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions
Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although
More informationBirth defects. Report by the Secretariat
EXECUTIVE BOARD EB126/10 126th Session 3 December 2009 Provisional agenda item 4.7 Birth defects Report by the Secretariat 1. In May 2009 the Executive Board at its 125th session considered an agenda item
More informationCONGENITAL HEART DISEASE
CONGENITAL HEART DISEASE Introduction Congenital heart disease (CHD) is the most common congenital disorder in newborns [1]. Due to definitional issues, there are large variations in prevalence estimates.
More informationCurrent Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma
No. 287, February 2013 Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma This committee opinion has been prepared by
More informationTrisomy 13 (also called Patau s syndrome or T13)
Screening Programmes Fetal Anomaly Trisomy 13 (also called Patau s syndrome or T13) Information for parents Publication date: April 2012 Review date: April 2013 Version 2 117 Information sheet to help
More informationA test your patients can trust. A company you know and trust.
A test your patients can trust. A company you know and trust. informaseq Prenatal Test an advanced, non-invasive, prenatal screening for T21, T18, and T13 chromosomal aneuploidies using next generation
More informationAssessment of Fetal Growth
Assessment of Fetal Growth Unit / Trust: 1. INTRODUCTION The aim of this guideline template is to outline the methods used to assess fetal growth and the referral pathways utilising customised antenatal
More informationClinical Policy: Ultrasound in Pregnancy Reference Number: CP.MP.38
Clinical Policy: Reference Number: CP.MP.38 Effective Date: 02/11 Last Review Date: 08/15 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and
More informationPrenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy This statement has been
More informationSonographic Accuracy of Estimated Fetal Weight in Twins
ORIGINAL RESEARCH Sonographic Accuracy of Estimated Fetal Weight in Twins Lorie M. Harper, MD, MSCI, Kimberly A. Roehl, MPH, Methodius G. Tuuli, MD, MPH, Anthony O. Odibo, MD, MSCE, Alison G. Cahill, MD,
More informationGenetics and Pregnancy Loss
Genetics and Pregnancy Loss Dorothy Warburton Genetics and Development (in Pediatrics) Columbia University, New York Estimates of Pregnancy Loss from Conception 1000 fertilized eggs (27% are lost) 728
More informationFirst-Trimester Cesarean Scar Pregnancy Evolving Into Placenta Previa/Accreta at Term
Case Report First-Trimester Cesarean Scar Pregnancy Evolving Into Placenta Previa/Accreta at Term Jara Ben Nagi, MD, Dede Ofili-Yebovi, MD, Mike Marsh, MD, Davor Jurkovic, MD Placenta accreta is a rare
More informationSOFT FETAL ULTRASOUND FINDINGS
SOFT FETAL ULTRASOUND FINDINGS Compiled by the Genetics Team at The Credit Valley Hospital Last updated February 2008 Page 2 This document refers to the ultrasound finding of a soft sign, as compared
More informationA single center experience with 1000 consecutive cases of multifetal pregnancy reduction
A single center experience with 1000 consecutive cases of multifetal pregnancy reduction Joanne Stone, MD, Keith Eddleman, MD, Lauren Lynch, MD, and Richard L. Berkowitz, MD New York, NY, and San Juan,
More informationGutenberg Center in MALAGA
Introduction Gutenberg Center in MALAGA Gutenberg Center in Málaga opened in 1987 as a clinic to provide integral assisstance for women, divided into 6 Units, specialized in the different aspects of Obs
More informationA. Evidence for an individually adjustable standard to assess birth weight:
Customised antenatal growth charts are designed to facilitate better supervision of fetal growth. The chart is printed out in early pregnancy, after confirmation of pregnancy dates, and allows serial plotting
More informationFetal Prognosis in Varix of the Intrafetal Umbilical Vein
Fetal Prognosis in Varix of the Intrafetal Umbilical Vein Waldo Sepulveda, MD, Antonio Mackenna, MD, Jorge Sanchez, MD, Edgardo Corral, MD, Eduardo Carstens, MD To assess the clinical significance of varix
More informationSWISS SOCIETY OF NEONATOLOGY. Umbilical cord complications in two subsequent pregnancies
SWISS SOCIETY OF NEONATOLOGY Umbilical cord complications in two subsequent pregnancies June 2006 2 Hetzel PG, Godi E, Bührer C, Department of Neonatology (HPG, BC), University Children s Hospital, Basel,
More informationParvovirus B19 Infection in Pregnancy
Parvovirus B19 Infection in Pregnancy Information Pack Parvovirus B19 Infection in Pregnancy Information Booklet CONTENTS: THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT
More informationIsolated Sonographic Markers for Detection of Fetal Down Syndrome in the Second Trimester of Pregnancy
Isolated Sonographic Markers for Detection of Fetal Down Syndrome in the Second Trimester of Pregnancy David A. Nyberg, MD, Vivienne L. Souter, MD, Amira El-Bastawissi, MBCB, PhD, Scott Young, MD, Fred
More informationFirst- and Second-Trimester Evaluation of Risk for Down Syndrome
Original Research First- and Second-Trimester Evaluation of Risk for Down Syndrome Robert H. Ball, MD, Aaron B. Caughey, MD, MPP, Fergal D. Malone, MD, David A. Nyberg, MD, Christine H. Comstock, MD, George
More informationIntrauterine sonographic assessments of embryonic heart diameter
Human Reproduction vol.12 no.10 pp.2286 2291, 1997 Intrauterine sonographic assessments of embryonic heart diameter Toshiyuki Hata 1, Daisaku Senoh, Kohkichi Hata and Kohji Miyazaki Department of Obstetrics
More informationThe ultrasound detection of chromosomal anomalies 1
The ultrasound detection of chromosomal anomalies 1 Werther Adrian Clavelli, MD 2, Silvia Susana Romaris de Clavelli, MD 2, Philippe Jeanty, MD, PhD 3 Adapted from The Ultrasound Detection of Chromosomal
More informationPlacenta, Cord, & Fluid
, Cord, & Fluid Abruption Accreta/Increta/Percreta Chorioangioma Complete Partial Not generally Relevant to U/S Gestational Age (Weeks) Distance from 16-23.9 24 to Internal Os >20 mm No No 11-20 mm 0-10
More informationUltrasound scans in pregnancy
Ultrasound scans in pregnancy www.antenatalscreening.wales.nhs.uk Copyright 2016 Public Health Wales NHS Trust. All rights reserved. Not to be reproduced in whole or in part without the permission of the
More informationComplimentary and personal copy for
Complimentary and personal copy for www.thieme.com Publishing House and Copyright: 2015 by Georg Thieme Verlag KG Rüdigerstraße 14 70469 Stuttgart ISSN Any further use only by permission of the Publishing
More informationRisk Calculation Software Requirements for Down's Syndrome Screening
Screening Programmes Fetal Anomaly Risk Calculation Software Requirements for Down's Syndrome Screening Version 1 January 2013 Created by: Dave Wright, Barry Nix, Steve Turner, David Worthington and Andy
More informationBELIEVE MIDWIFERY SERVICES, LLC
, LLC TITLE: ESTABLISHING the GESTATIONAL AGE & ROUTINE ULTRASOUND EFFECTIVE DATE: November 11th, 2013 POLICY STATEMENT Establishing accurate pregnancy dating impacts the management of normal and abnormal
More informationDifferentiation between normal and abnormal fetal growth
Differentiation between normal and abnormal fetal growth JASON GARDOSI MD FRCSE FRCOG Director, West Midlands Perinatal Institute, St Chad s Court, 213 Hagley Road, Birmingham B16 9RG, U.K. Tel +44 (0)121
More informationSaint Mary s Hospital Tests for you and your baby during pregnancy
Maternity Service Saint Mary s Hospital Tests for you and your baby during pregnancy Contents Page What is this leaflet about? 3 Routine blood tests for the mother 4 Anaemia 4 Blood group 4 German measles
More informationPrenatal Screening Policies in Europe
Prenatal Screening Policies in Europe 2010 EUROCAT Central Registry Room 12L09, University of Ulster Newtownabbey, Co Antrim Northern Ireland, BT37 0QB Tel: +44 (0)28 90366639 Fax: +44 (0)28 90368341 Email:
More informationThe First Trimester Screening program
The First Trimester Screening program The Fetal Medicine Foundation This guide has been designed to highlight the important clinical aspects of using the First Trimester Screening program. It is not intended
More informationINTERGROWTH-21 st International Fetal and Newborn Growth Standards for the 21 st Century
INTERGROWTH-21 st CRL standardization 1 INTERGROWTH-21 st International Fetal and Newborn Growth Standards for the 21 st Century The International Fetal and Newborn Growth Consortium Correct measurement
More informationEffect of incorrect gestational dating on Down s syndrome and neural tube risk assessment
Original Article Ann Clin Biochem 2001; 38: 230±234 Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment S N Millner From the Department of Pathology, University of
More informationEffect of Increased Body Mass Index on the Accuracy of Estimated Fetal Weight by Sonography in Twins
Article Effect of Increased Body Mass Index on the Accuracy of Estimated Fetal Weight by Sonography in Twins Manisha Gandhi, MD, Lauren Ferrara, MD, Victoria Belogolovkin, MD, Erin Moshier, MS, Andrei
More informationScreening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine Practice Policy Statement
ATTENTION This Policy was reaffirmed by the ACPM Board of Regents on 1/31/2005 and is effective through 1/31/2010. Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine
More informationThe costs of having a baby. Private system
The costs of having a baby Private system Contents Introduction 4 Weeks 1 4 5 Week 5 5 Week 6 6 Week 10 6 Week 11 7 Week 12 8 Week 15 8 Week 16 9 Week 20 9 Week 21 10 Week 22 10 Week 26 11 Week 32 11 Week
More informationFetal loss following ultrasound diagnosis of a live fetus at 6 10 weeks of gestation
Ultrasound Obstet Gynecol 23; 22: 368 372 Published online 2 September 23 in Wiley InterScience (www.interscience.wiley.com). DOI: 1.12/uog.24 Fetal loss following ultrasound diagnosis of a live fetus
More informationREPRODUCTIVE ENDOCRINOLOGY
FERTILITY AND STERILITY VOL. 82, NO. 5, NOVEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY
More information